PRESS
KIT
2024

00 CONTENTS

01

THE COMPANY

3

General information..................................................... 4
Business divisions....................................................... 5
Greiner Bio-One International GmbH............................ 602

KEY FACTS

FINANCIAL YEAR 2022

10

MILESTONES

16

Success story of Greiner Bio-One.............................. 17

05

PRODUCTS

18

Preanalytics Portfolio................................................ 19
BioScience Portfolio.................................................. 21

7

Greiner Bio-One International GmbH............................ 8
Company headquarters............................................... 9

03

04

06

FURTHER INFORMATION

23

Additional links.......................................................... 24
Contact partners....................................................... 25

Management change................................................. 11
Innovative product solutions..................................... 12
Investments............................................................... 13
Business development in 2023 .................................. 14
Outlook for 2024......................................................... 15© Greiner Bio-One GmbH 2024

page 2 / 26

01

© Greiner Bio-One GmbH 2024

THE
COMPANY

page 3 / 26

01 THE COMPANY

GENERAL INFORMATIONGENERALINFORMATION

Greiner Bio-One specialises in the development, production and

BUSINESS UNITS

The company is a technology partner for hospitals, laboratories, universities,

GREINER BIO-ONE
INTERNATIONAL GMBH

distribution of high-quality plastic laboratory products.

research institutes, and the diagnostic, pharmaceutical and biotechnology
industries.
The medical technology company is divided into the three business divisions
Preanalytics, BioScience and Mediscan.
As an Original Equipment Manufacturer (OEM), Greiner Bio-One is also a solid
partner for industry clients working in pharmaceuticals, biotechnology,
diagnostics and medical technology and offers customised design
development and production processes.

© Greiner Bio-One GmbH 2024

page 4 / 26

01 THE COMPANY

BUSINESS UNITS
GENERALINFORMATION
BUSINESS UNITSGREINER BIO-ONE
INTERNATIONAL GMBH

The Preanalytics business unit, with headquarters in Kremsmünster(Austria), develops and produces innovative collection systems for humanand veterinary blood, urine and saliva samples, with the aim of making dayto-day, routine tasks in hospitals, laboratories and doctors’ practices easierand safer. This division also covers software solutions (Tracie Healthcare
Solutions) which ensure greater efficiency and patient safety in thepreanalytical process.
Innovative collection systems for human and veterinary samples from blood, urine and saliva

Greiner Bio-One’s BioScience unit, with headquarters in Frickenhausen(Germany), is one of the leading suppliers with a wide range of specialist
products for the cultivation and analysis of cell and tissue cultures. Basedon decades of experience in the cryopreservation of samples, Greiner
Bio-One also offers solutions for automated storage systems in biobanks.
In addition, the division also develops and produces microplates for highthroughput screening, which ensure the quickest and most efficient testingof substances and materials in both industry and research.
Special products for the cultivation and analysis of cell and tissue cultures

Greiner Bio-One’s third business unit is Mediscan, a wholly-owned subsidiaryof Greiner Bio-One International with headquarters in Kremsmünster(Austria). Mediscan is a skilled service provider in the field of sterilisation of
medical products and food packaging, and also specialises in improving thefunction of plastics and semiconductors using ionising radiation.

Sterilization by means of ionizing radiation© Greiner Bio-One GmbH 2024

page 5 / 26

01 THE COMPANY

GENERALINFORMATION
BUSINESS UNITSGREINER BIO-ONE
INTERNATIONAL GMBH

© Greiner Bio-One GmbH 2024

page 6 / 26

02 KEY FACTS© Greiner Bio-One GmbH 2024

page 7 / 26

02 KEY FACTS

GREINER BIO-ONE INTERNATIONAL GMBH
GREINER BIO-ONE
INTERNATIONAL GMBH
COMPANYHEADQUARTERS© Greiner Bio-One GmbH 2024

MANAGEMENT

Kremsmünster, Austria

CEO Ilke Panzer

LOCATIONSSALES PARTNERS

29 subsidiaries

Distributors in morethan 100 countries

Turnover

Employees

637

MIO. EURO

2,659

page 8 / 26

2023

HEADQUARTERS

02 KEY FACTS

COMPANY HEADQUARTERS
GREINER BIO-ONE
INTERNATIONAL GMBH

GREINER BIO-ONE GMBH
PREANALYTICSCOMPANYHEADQUARTERS

OFFICE LOCATIONPRODUCTION

Kremsmünster, Austria

Preanalytics products

EMPLOYEESMANAGEMENT

679

Thomas Scheurecker
Georg Heftberger
Kruno Obrovac

Greiner Bio-One GmbH Preanalytics (Kremsmünster, Austria)

GREINER BIO-ONE GMBH
BIOSCIENCE
OFFICE LOCATIONPRODUCTION

Frickenhausen, Germany

BioScience products

EMPLOYEESMANAGEMENT

408

Bernd Klingel

Greiner Bio-One GmbH BioScience (Frickenhausen, Germany)© Greiner Bio-One GmbH 2024

page 9 / 26

03 FINANCIAL
YEAR 2023© Greiner Bio-One GmbH 2024

page 10 / 26

03 FINANCIAL YEAR
2022

MANAGEMENT CHANGE

MANAGEMENT CHANGE

In the summer of 2023, a decision was made to place the division's
management in new hands. Manfred Stanek, COO of Greiner AG, also

INNOVATIVE PRODUCTSOLUTIONS

temporarily assumed the role of CEO of Greiner Bio-One from the

INVESTMENTS

Ilke Panzer took over as the new division manager on February 1, 2024.

BUSINESSDEVELOPMENT
IN 2023
OUTLOOK FOR 2024

previous division manager, Rainer Perneker.

She was born in Germany and has spent most of her career in the USA.
Most recently, she worked as a freelance consultant in healthcare
innovation. Having gained leadership experience at Assurance“We want to contribute toremarkable successes inmedicine and make a realdifference for users andpatients.”

Laboratories LLC, BloodCenter Wisconsin, and Johnson & Johnson,
she can contribute extensive knowledge from the healthcare andpharmaceutical industries.
She began her career at General Electric, where her roles included
General Manager of the Global Ultrasound business. Panzer studied
engineering, computer and systems engineering at the University ofConnecticut, USA, and at the National Technological University in Fort
Collins, Colorado. She has been a member of the Supervisory Board of
the German pharmaceutical and laboratory supplier Sartorius AG since
2017.

Ilke Panzer, CEO Greiner Bio-One International GmbH(c) Silvia Wittmann© Greiner Bio-One GmbH 2024

page 11 / 26

03 FINANCIAL YEAR
2022

INNOVATIVE PRODUCT SOLUTIONSMANAGEMENT CHANGE

The new VACUETTE® CAT serum fast separator tube combines the speedof a plasma tube with the quality of serum in terms of the red blood cells

INNOVATIVE PRODUCTSOLUTIONSINVESTMENTS
BUSINESSDEVELOPMENT
IN 2023
OUTLOOK FOR 2024

remaining after centrifugation. The turn-around time (TAT; time between
blood collection and obtaining the results) is significantly shortened by the
new tube. Thanks to the short clotting time of just five minutes and thesubsequent five-minute centrifugation, analysis can begin after ten shortminutes and treatment started more quickly. The inside of the shatterproof
tube is coated with a mixture of blood-clotting activator and thrombin. Aftercentrifugation, the added gel forms a stable barrier between the serum andthe solid components. The thrombin in the additive accelerates the clotting
process.

VACUETTE ® CAT Serum Fast Separator Tubes

The tried and proven ThinCert® cell culture inserts are successfully usedworldwide for demanding cell and tissue culture applications. The current
portfolio consists of individual membrane-based cell culture inserts for
6, 12, or 24 well plates. The new 96 well HTS variant allows for automation,
increases throughput and thus saves time and costs compared to thesingle-insert solutions. The new ThinCert® HTS insert product variants
with pore sizes of 3 µm or 8 µm are particularly suitable for migration andinvasion studies, which play a decisive role in physiological and pathologicalprocesses such as the migration of immune cells, wound healing processes,or the metastasis of tumor tissue.

© Greiner Bio-One GmbH 2024

ThinCert® 96-well HTS insert

page 12 / 26

03 FINANCIAL YEAR
2022

MANAGEMENT CHANGE

INVESTMENTS
Greiner Bio-One’s production volumes and demand for sterilization
service providers have increased since the last site expansion in 2015.

INNOVATIVE PRODUCTSOLUTIONSINVESTMENTS
BUSINESSDEVELOPMENT
IN 2023

This is why an additional plant for sterilizing medical products andfood packaging and refining plastics and semiconductors is being built
adjacent to the existing plant in Kremsmünster. The plant technology
meets the latest standards, has been technologically enhanced
compared to the predecessor model and once again combines two
different treatment technologies in a single plant that is scheduled to
go into operation in mid-2024. Its future capacity will make it Europe’s

Europe's largest sterilization plantlargest sterilization facility.

OUTLOOK FOR 2024

A new warehouse and office building was built at the sales branch in the
UK in 2023. The new building, located just 800 meters away from theprevious site, has an area of 53,500 square meters and boasts twice asmuch storage space as the old location. These new warehouse facilities
and improved incoming and outgoing goods processes ensure better
logistics management. In moving to the new building, Greiner Bio-One
is laying the foundations for further growth. The new site has been fully
operational since the start of 2024.
New warehouses and office buidlings for Greiner Bio-One UK© Greiner Bio-One GmbH 2024

page 13 / 26

03 FINANCIAL YEAR
2022

MANAGEMENT CHANGE

BUSINESS DEVELOPMENT IN 2023
Last year, Greiner Bio-One 637 million euros in sales revenue, a decline of 8.1
percent.

INNOVATIVE PRODUCTSOLUTIONSINVESTMENTS
BUSINESSDEVELOPMENT
IN 2023
OUTLOOK FOR 2024

As the COVID-19 pandemic subsided and disrupted supply chains were
restored, customers across the industry built up massive inventories, which inturn led to a decline in current demand. The business unit is also challenged byhigh inflation and interest rates, which have significantly driven up production
costs at its main facilities.
Incoming orders in Preanalytics declined slightly but remained at a high level.
In the BioScience unit, Greiner Bio-One continued to feel the effects of thecost-cutting measures taken by many research institutes: projects were
postponed and fewer consumables were needed.

© Greiner Bio-One GmbH 2024

page 14 / 26

03 FINANCIAL YEAR
2022

MANAGEMENT CHANGEOUTLOOK FOR 2024:
PROFITABLE GROWTH
Greiner Bio-One will continue to focus on profitable growth in the current year in order to be able
to finance important projects and investments. In the Preanalytics and BioScience business

INNOVATIVE PRODUCTSOLUTIONSINVESTMENTS
BUSINESSDEVELOPMENT
IN 2023
OUTLOOK FOR 2024

units, Greiner Bio-One is building on its core products to further strengthen its position in themarket. In addition to its home markets in Europe, the company sees great potential for further
expansion of its global market share, particularly in Asia and the USA. The current challenging
market situation notwithstanding, we will complete the ongoing infrastructure investments in
Brazil and Austria (Kremsmünster) as well as the capacity expansions in individual product groups
in both business units (TC tubes, roller bottles, HTS plates, and blood tubes). These measures will
help to support the expected upturn in 2024.
Greiner Bio-One will continue to focus on equipping the company and its employees for thedemands of the future and thus for sustainable growth in 2024. In this context, Greiner Bio-One
also established a Sustainability Council to implement theGroup-wide topics and meet related customer needs, improve product sustainability and reduce
Scope 3 emissions.

© Greiner Bio-One GmbH 2024

page 15 / 26

04 MILESTONES© Greiner Bio-One GmbH 2024

page 16 / 26

04 MILESTONESSUCCESS STORY OF GREINER BIO-ONE© Greiner Bio-One GmbH 2024

With the rapid
development of
the VACUETTE®
virus stabilization
tube and a focus
on COVID-19
relevant products,
Greiner Bio-One ismakinga key contribution
to the conquest of
the pandemic.

2023

VACUETTE®
EVOPROTECT
represents thenext stage inblood collection.
It protects theuser from the riskof needlestick
injuries andprovidessubstantial
support for safe
blood collection.

2022

Incorporation ofMediscaninto the Greiner
Bio-One Group.

2021

2018

Through its
acquisition of 3D
cell culture assets
from Nano3D
Biosciences, Inc.,
Greiner Bio-One
becomes a leadinginternational
provider in thefield of threedimensional cell
cultivation.

2020

GreinerLabortechnik
already has aninternationalfooting andexpands further.
In 2000, thecompany isrebrandedfrom Greiner
Labortechnik to
Greiner Bio-One.

Introductionof the firstsafetyproducts
in theVACUETTE®
line.

2003

2001

Greiner develops
the world’s
first 1536 Well
Microplate.
The plates areused to test
substances for
manufacturing
medication.

2000

The world’s
first evacuatedblood collection
system madeof only plastic
is launched.
Many further
developments
follow in the next
few years.

1997

Company foundedas Greiner
Labortechnik(now : Greiner
Bio-One)Greiner starts
life in Nürtingen(Germany) withthe manufactureof the first plastic
Petri dishes.

1987

1963

SUCCESS STORYOF GREINER BIO-ONE

Greiner Bio-One
celebrates its
anniversary.
Even after 60
years, we standmore than everfor technology,
quality andglobal presence.

On 1 March 2022,
Tracie Healthcare
Solutions, astart-up from
Bridgemaker andGreiner Bio-One,
is founded. Tracie
digitizes the entire
preanalyticalsample process
and reduces theerror rate.

page 17 / 26

05 PRODUCTS© Greiner Bio-One GmbH 2024

page 18 / 26

05 PRODUCTS

PREANALYTICS PORTFOLIOPREANALYTICSPORTFOLIO
BIOSCIENCEPORTFOLIO

Greiner Bio-One offers an extensive product portfolio not only for routine procedures
but also for specialist areas of application in pre and postanalytics. The portfolio ranges
from evacuated blood collection tubes, urine tubes and containers as well as many otheraccessories and safety products, through to ESR (erythrocyte sedimentation rate) systems,
transport and disposal containers, and a diverse range of auxiliary devices such as decapping
instruments.

COLLECTION SYSTEMS FOR
BLOOD AND URINE
The VACUETTE® line comprises innovative sample collection systems
for blood, urine and saliva. The collection tubes contain a pre-dosed
vacuum and an additive which is required for further processing. All of our
VACUETTE® tubes make sample collection easy, ensure the same mixing
ratio every time and guarantee reliable test results.
VACUETTE® tubes

MiniCollect® offers a gentle way to collect small blood samples for a wide
range of analyses. The system is perfectly suited for young children,
geriatric patients as well as patients with fragile veins.

MiniCollect® system© Greiner Bio-One GmbH 2024

page 19 / 26

05 PRODUCTS

PREANALYTICSPORTFOLIO
BIOSCIENCEPORTFOLIO

SAFETY PRODUCTS
Safety is our top priority! The risk of injury and contamination can besignificantly reduced by using safety products such as cannulae withprotective caps, safety tube holders or safety blood collection sets forsample collection.

ACCESSORIESVACUETTE® safety products

The Greiner Bio-One range for the field of preanalytics comprises additional
accessories for venous blood collection (tube holders, blood collection sets
and cannulae, snap caps, etc.) and capillary blood collection (carrier tubes,
funnels, etc.), urine collection (urine sets, cups, collection containers, etc.),
as well as accessories for disposal boxes and transportation

TRANSPORT, DISPOSAL AND DEVICES
In order to ensure the safe transportation of samples, Greiner Bio-One

VACUETTE® accessories

offers transport boxes and containers. The range also includes a diverse
selection of decapping and ESR devices as well as disposal boxes in avariety of sizes to suit different requirements.

VACUETTE® transport line

© Greiner Bio-One GmbH 2024

page 20 / 26

05 PRODUCTS

BIOSCIENCE PORTFOLIOPREANALYTICSPORTFOLIO
BIOSCIENCEPORTFOLIO

Greiner Bio-One’s BioScience division is one of the leading providers of specialist products
for the cultivation and analysis of cell and tissue cultures. Based on decades of experiencein the cryopreservation of samples, Greiner Bio-One also offers solutions for automatedstorage systems in biobanks. In addition, the division also develops and produces
microplates for high-throughput screening, which ensure the quickest and most efficienttesting of substances and materials in both industry and research.

PRODUCTS FOR CELL CULTURE,
MASS CELL CULTURE AND 3D CELL CULTURE
With the CELLSTAR ® product line, Greiner Bio-One BioScience develops andsells products for the cultivation, storage and separation of cells as well as
for specific applications in medical, pharmaceutical and biotechnologicalresearch. In addition, the company offers solutions for the automation andscale-up of mass cell cultures as well as for 3D cell cultivation.
CELLSTAR ® cell culture flasks© Greiner Bio-One GmbH 2024

page 21 / 26

05 PRODUCTS

PREANALYTICSPORTFOLIO
BIOSCIENCEPORTFOLIOPRODUCTS FOR HIGH-THROUGHPUT SCREENING(HTS)
For decades, Greiner Bio-One has been producing plastic microplates thatare used in laboratories all over the world for diagnostics and research.
Microplates enable quick, automated analysis of a range of substances. It is
this high level of efficiency that ensures the successful development of new
medication, for example. Alongside microplates for use in pharmaceuticalsubstance testing, the company also provides special plates for
immunology, protein crystallisation and DNA analysis.

Microplates for high-throughput screening (HTS)PRODUCTS FOR THE CRYOPRESERVATION
OF SAMPLES
When it comes to freezing and storing samples, Greiner Bio-One has acomprehensive product portfolio consisting of Cryo.s freezing tubes, racks
and electronic accessories for opening and closing tubes as well as forsample tracking.

Cryo.s and biobanking tubes

PRODUCTS FOR GENERAL LABORATORY USE
AND LIQUID HANDLING
Greiner Bio-One’s product portfolio for the variety of activities carried out
in laboratories comprises products such as pipettes and pipette tips forhandling liquids, as well as small devices that allow work with a wide varietyof sample materials.
Sapphire pipette tips

© Greiner Bio-One GmbH 2024

page 22 / 26

06 FURTHERINFORMATION© Greiner Bio-One GmbH 2024

page 23 / 26

06 FURTHERINFORMATION

ADDITIONAL LINKS
ADDITIONAL LINKSIMAGESCONTACT PARTNERS

https://mam.greiner.at/pinaccess/showpin.do?pinCode=m91t2tkV4WWJ
If you require additional images, please get in touch with the press contact
for the relevant business division as specified on the following page.

PRESS RELEASES
https://www.gbo.com/en-int/press-events/press
If you require additional information, please get in touch with the press contact
for the relevant business division as specified on the following page.

TRADE FAIRS AND EVENTS
https://www.gbo.com/en-int/press-events/events© Greiner Bio-One GmbH 2024

page 24 / 26

06 FURTHERINFORMATIONCONTACT PARTNERS
ADDITIONAL LINKS

Mag. Gudrun Miglbauer-Badurek
Director Corporate Communication

CONTACT PARTNERS

corp.communication@gbo.com
Julia Franke, MA
Expert Global Communication
corp.communication@gbo.com© Greiner Bio-One GmbH 2024

page 25 / 26

GREINER BIO-ONE
INTERNATIONAL GMBHKREMSMÜNSTER, AUSTRIA
PHONE
E-MAIL+43 7583 6791 0
office@gbo.com

www.gbo.com
May 2024